Myeloproliferative Neoplasms

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.

Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.

The FDA has accepted a new drug application seeking the approval of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.

John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.

Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Marina Kremyanskaya, MD, PhD, details the outcomes of the phase 2 trial, expands on the potential implications for rusfertide in the treatment of patients with PV, and detailed the next steps for investigating the agent in this patient population.